Modelling the health and economic impacts of M72/AS01E vaccination and BCG-revaccination: Estimates for South Africa
Open Access
- 2 February 2024
- Vol. 42 (6) , 1311-1318
Abstract
No abstract availableKeywords
Funding Information
- Engineering and Physical Sciences Research Council (EP/P020267/1)
- University of Edinburgh
- Bill & Melinda Gates Foundation (INV-001754)
This publication has 18 references indexed in Scilit:
- The impact of alternative delivery strategies for novel tuberculosis vaccines in low-income and middle-income countries: a modelling studyThe Lancet Global Health, 2023
- Demonstrating multi-country calibration of a tuberculosis model using new history matching and emulation package - hmerEpidemics, 2023
- Feasibility of novel adult tuberculosis vaccination in South Africa: a cost-effectiveness and budget impact analysisnpj Vaccines, 2022
- Prevalence of bacteriologically confirmed pulmonary tuberculosis in South Africa, 2017–19: a multistage, cluster-based, cross-sectional surveyThe Lancet Infectious Diseases, 2022
- Cost-effectiveness of routine adolescent vaccination with an M72/AS01E-like tuberculosis vaccine in South Africa and IndiaNature Communications, 2022
- Final Analysis of a Trial of M72/AS01 E Vaccine to Prevent TuberculosisNew England Journal of Medicine, 2019
- Prevention of M. tuberculosis Infection with H4:IC31 Vaccine or BCG RevaccinationNew England Journal of Medicine, 2018
- BCG vaccine: WHO position paper, February 2018 – RecommendationsVaccine, 2018
- Safety and immunogenicity of candidate vaccine M72/AS01E in adolescents in a TB endemic settingVaccine, 2015
- The social epidemiology of tuberculosis in South Africa: A multilevel analysisSocial Science & Medicine, 2008